VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company is pleased to announce that it will present its Phase 2a Ifenprodil cough data at the 9th American Cough Conference (ACC) being held June 9-10, 2023 in Reston, Virginia.


Previous articleAlgernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
Next articleCOMPASS Pathways’ key patents upheld by the US Patent and Trademark Office